 Cetuximab
"Cetuximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.
| Descriptor ID |
D000068818
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.750 D12.776.124.790.651.114.224.060.750 D12.776.377.715.548.114.224.200.750
|
| Concept/Terms |
IMC C225- IMC C225
- C225, IMC
- IMC-C225
- IMCC225
- MAb C225
- C225, MAb
- C225
|
Below are MeSH descriptors whose meaning is more general than "Cetuximab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Cetuximab [D12.776.124.486.485.114.224.060.750]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Cetuximab [D12.776.124.790.651.114.224.060.750]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Cetuximab [D12.776.377.715.548.114.224.200.750]
Below are MeSH descriptors whose meaning is more specific than "Cetuximab".
This graph shows the total number of publications written about "Cetuximab" by people in this website by year, and whether "Cetuximab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cetuximab" by people in Profiles.
-
Greening DW, Lee ST, Ji H, Simpson RJ, Rigopoulos A, Murone C, Fang C, Gong S, O'Keefe G, Scott AM. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget. 2015 Nov 10; 6(35):38166-80.
-
George TJ, O'Connell MJ. A new predictive molecular marker for cetuximab benefit in rectal cancer? J Natl Cancer Inst. 2014 Jul; 106(7).
-
George TJ, Laplant KD, Walden EO, Davis AB, Riggs CE, Close JL, George SN, Lynch JW. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. J Support Oncol. 2010 Mar-Apr; 8(2):72-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|